Sanofi B.V.
10 products tracked · names used in filings: Sanofi B.V.
Upcoming milestones
No upcoming milestones listed.
Recent milestones
Mon 22 Dec 2025🇪🇺 EU approval (EC decision)
Wayrilz (rilzabrutinib) approved in the EU
Marketing authorisation to Sanofi B.V.; Orphan, Additional monitoring · source
Thu 16 Oct 2025🇪🇺 CHMP positive opinion
Wayrilz (rilzabrutinib): CHMP positive opinion
Sanofi B.V.; Orphan, Additional monitoring · source
Products
| Product | Status | Approved | |
|---|---|---|---|
| 🇪🇺 | Wayrilz rilzabrutinib | Authorised | 2025-12-22 |
| 🇪🇺 | Xenpozyme olipudase alfa | Authorised | 2022-06-24 |
| 🇪🇺 | Nexviadyme avalglucosidase alfa | Authorised | 2022-06-24 |
| 🇪🇺 | Cerdelga eliglustat | Authorised | 2015-01-19 |
| 🇪🇺 | Mozobil plerixafor | Authorised | 2009-07-30 |
| 🇪🇺 | Evoltra clofarabine | Authorised | 2006-05-29 |
| 🇪🇺 | Myozyme alglucosidase alfa | Authorised | 2006-03-28 |
| 🇪🇺 | Aldurazyme laronidase | Authorised | 2003-06-09 |
| 🇪🇺 | Fabrazyme agalsidase beta | Authorised | 2001-08-03 |
| 🇪🇺 | Cerezyme imiglucerase | Authorised | 1997-11-17 |
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.